Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study.

Victor Chien-Chia Wu Chien-Hao Huang Chun-Li WangMeng-Hung LinTing-Yu KuoChih-Hsiang ChangMichael WuShao-Wei Chen Shang-Hung Chang Pao-Hsien ChuCheng-Shyong WuYu-Sheng Lin

Published in: European heart journal. Cardiovascular pharmacotherapy (2023)

Chronic HCV patients treated with DAA experienced lower rates of cardiovascular events and all-cause mortality than those without treatment. The reduction of VTE was the most significant impact of DAA treatment among the cardiovascular outcomes.

Keyphrases

hepatitis c virus
cardiovascular events
coronary artery disease
human immunodeficiency virus
cardiovascular disease
stem cells
bone marrow
combination therapy
type diabetes
hiv infected
drug induced
replacement therapy